Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O75923: Variant p.Val67Asp

Dysferlin
Gene: DYSF
Feedback?
Variant information Variant position: help 67 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Valine (V) to Aspartate (D) at position 67 (V67D, p.Val67Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (V) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In MMD1 and LGMDR2; Reduces calcium-sensitive phospholipid binding and interaction with AHNAK and AHNAK2. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 67 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2080 The length of the canonical sequence.
Location on the sequence: help NEGFEWDLKGIPLDQGSELH V VVKDHETMGRNRFLGEAKVP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         NEGFEWDLKGIPLDQGSELHVVVKDHETMGRNRFLGEAKVP

Mouse                         NEGFEWDLKGIPLDQSSELLVVVKDHETMGRNRFLGEAKIP

Bovine                        NEGFEWDLKGIPLDQGSELLVVVKDHETMGRNRFLGEANIP

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 2080 Dysferlin
Topological domain 1 – 2046 Cytoplasmic
Domain 1 – 101 C2 1
Mutagenesis 71 – 71 D -> A. Fails to bind calcium.
Mutagenesis 79 – 79 R -> D. Moderately increased calcium affinity.
Mutagenesis 80 – 80 F -> A. Reduced calcium affinity.
Beta strand 64 – 71



Literature citations
Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains.
Davis D.B.; Doherty K.R.; Delmonte A.J.; McNally E.M.;
J. Biol. Chem. 277:22883-22888(2002)
Cited for: TISSUE SPECIFICITY; CHARACTERIZATION OF VARIANT MMD1 ASP-67; AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration.
Huang Y.; Laval S.H.; van Remoortere A.; Baudier J.; Benaud C.; Anderson L.V.; Straub V.; Deelder A.; Frants R.R.; den Dunnen J.T.; Bushby K.; van der Maarel S.M.;
FASEB J. 21:732-742(2007)
Cited for: INTERACTION WITH AHNAK AND AHNAK2; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANT LGMDR2 ASP-67; TISSUE SPECIFICITY; IDENTIFICATION BY MASS SPECTROMETRY; Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy.
Illarioshkin S.N.; Ivanova-Smolenskaya I.A.; Greenberg C.R.; Nylen E.; Sukhorukov V.S.; Poleshchuk V.V.; Markova E.D.; Wrogemann K.;
Neurology 55:1931-1933(2000)
Cited for: VARIANT MMD1 ASP-67; VARIANT LGMDR2 ASP-67;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.